Identification of impurities and their amounts in the atorvastatin bulk drug and tablet DIVASTINTM (20 mg) were done using HPLC with diode array detector. The composition of mobile phase was acetonitril:phosphate buffer (45:55%; pH 4.0) with flow rate of 0.5 mL/min and detected at 248 ± 8 nm. Four impurities (desfluoro atorvastatin, distereoisomer, 3-o-methyl atorvastatin and lactone atorvastatin) were detected in the bulk drug whereas five impurities were detected in the tablet DIVASTINTM (20 mg). The total amounts of impurities in atorvastatin bulk drug and tablet were 0.804 and 0.983% respectively. In conclusion, the total amount of impurities was less than 1% which is acceptable.
Introduction
Atorvastatin is a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor that has been demonstrated to be efficacious in reducing both cholesterol and triglyceride (Bakker-Arkema et al., 1996) . It is administered as the calcium salt of the active hydroxy acid and is used between 10 and 80 mg per day to reduce the raised lipid levels in patients with primary hyperlipidemia.
The presence of impurities in the tablets reflects the quality of the manufacturing process for the bulk drug, so that high manufacturing standards and practices should translate to reduced impurity levels). The presence of impurities even in small amounts may influence the efficacy and safety of the pharmaceutical products. There are 2 types of impurities in medicines: (1) impurities associated with active pharmaceutical ingredients and (2) impurities that are created during formulation and or with aging or that are related to the formulated forms (Roy, 2002) .
At least 20 impurities are identified of which four important impurities are atorvastatin diol methyl ester, lactone atorvastatin, diastereo-isomer atorvastatin, desfluoro-atorvastatin and 3-0-methyl atorvastatin. Atorvastatin lactam impurity is the photodegradation product.
The purpose of this study is to examine the presence of impurities in tablet DIVASTINTM. 
Materials and Methods
Chemicals: Atorvastatin and its five impuritiesdesfluoro atorvastatin, distereoisomer, 3-o-methyl atorvastatin, lactone atorvastatin, and diol methyl ester were supplied by Cadila Healthcare Ltd, Ahmedabad, India. HPLC grade acetonitril was purchased from E. Merck (Germany). Tablet DIVASTINTM (20 mg; atorvastatin calcium trihydrate, batch number: TAB/D 153:0509) was supplied by Drug International Ltd, Bangladesh. Chromatographic condition: The HPLC-UV diode-array system consisted of Agilent model 1200 series solvent delivery pump, degasser, autosampler, column oven and photo diode array detector. Chromatographic data were collected and analyzed using ChemStation software. A reverse-phase high performance liquid chromatography (HPLC) was used for the determination of atorvastatin both in atorvastatin bulk drug and tablet DIVASTINTM (20 mg) (Ertu¨rk et al., 2003) . The chromatographic analyses were performed on an Agilent 5 ?m C18 column (150 x 4.6 mm). The mobile phase used for analysis consisted of 45% acetonitril (HPLC grade; E. Merck, Germany) and 55% sodium dihydrogen phosphate buffer (pH 4.0, adjusted with ophosphoric acid) was delivered at a rate of 0.5 mL/min. The phosphate buffer was prepared freshly on each day of experiment and filtered using 0.45 m nylon filter. Separations were achieved at 50°C. The wavelength was set at 248 nm (bandwidth 8 nm). Injection of sample (20 ?L) was done using an autosampler. The peak with retention time and area were defined using software. Identification of impurities: One milligram of each impurity (desfluoro atorvastatin, distereoisomer, 3-omethyl atorvastatin, lactone atorvastatin, and diol methyl ester) was dissolve into the mobile phase separately and then diluted into different concentrations. One microgram of each sample was injected into the HPLC system separately to identify the peak using retention time. Then all the above mentioned impurities with atorvastation (1 g each) were mixed in mobile phase of which 20 L was injected. One tablet DIVASTINTM (20 mg) was powdered and dissolved in 20 mL of mobile phase (1 mg/mL). It was then diluted to 50 g/mL using mobile phase and finally filtered using syringe filter 0.22 m. Twenty microliter of the sample was injected into the HPLC system.
Results and Discussion
The peak of the standard desfluoro atorvastatin appeared first with a retention time of 17.4 min ( Figure  1 ). Other peaks were: distereoisomer (18.7 min), 3-omethyl atorvastatin (34.9 min), lactone atorvastatin (40.3 min) and diol methyl ester (53.0 min).
When atorvastation bulk drug was injected, all the peaks except diol methyl ester appeared in the chromatogram (Figure 2 ). Among the impurities highest amount (0.29%) was 3-o-methyl atorvastatin (peak 4, Table I ). The total amount of impurities in bulk drug was 0.804%. In case of tablet DIVASTINTM (20 mg) all the peaks including diol methyl ester peak were detected ( Figure  3 ). No unknown impurity was detected. Among the impurities 3-o-methyl atorvastatin showed highest amount (0.338%). The total amount of these impurities was 0.983%. Only 0.179% impurity was increased during the production of tablet.
According to ICH guidelines on impurities in drug products, identification of impurities below the 0.1% level is not considered to be necessary unless the potential impurities are expected to be unusually potent or toxic (International Conferences on Harmonization, 2000) . The maximum daily dose qualification threshold is considered to be less than 1 mg/day.
In conclusion, the amount of impurities in finished product (Tab. DIVASTINTM) was less than 1% which is acceptable.
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